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Abstract
Objectives This study aimed to compare the costs of a next-generation sequencing-based (NGS-based) panel testing strategy 
to those of a single-gene testing-based (SGT-based) strategy, considering different scenarios of clinical practice evolution.
Methods Three Italian hospitals were analysed, and four different testing pathways (paths 1, 2, 3, and 4) were identified: 
two for advanced non-small-cell lung cancer (aNSCLC) patients and two for unresectable metastatic colon-rectal cancer 
(mCRC) patients. For each path, we explored four scenarios considering the current clinical practice and its expected evolu-
tion. The 16 testing cases (4 scenarios × 4 paths) were then compared in terms of differential costs between the NGS-based 
and SGT-based approaches considering personnel, consumables, equipment, and overhead costs. Break-even and sensitivity 
analyses were performed. Data gathering, aimed at identifying the hospital setup, was performed through a semi-structured 
questionnaire administered to the professionals involved in testing activities.
Results The NGS-based strategy was found to be a cost-saving alternative to the SGT-based strategy in 15 of the 16 testing 
cases. The break-even threshold, the minimum number of patients required to make the NGS-based approach less costly than 
the SGT-based approach, varied across the testing cases depending on molecular alterations tested, techniques adopted, and 
specific costs. The analysis found the NGS-based approach to be less costly than the SGT-based approach in nine of the 16 
testing cases at any volume of tests performed; in six cases, the NGS-based approach was found to be less costly above a 
threshold (and in one case, it was found to be always more expensive). Savings obtained using an NGS-based approach ranged 
from €30 to €1249 per patient; in the unique testing case where NGS was more costly, the additional cost per patient was €25.
Conclusions An NGS-based approach may be less costly than an SGT-based approach; also, generated savings increase with 
the number of patients and different molecular alterations tested.
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Key Points for Decision Makers 
Testing strategies for advanced non-small-cell lung 
cancer and unresectable metastatic colon-rectal cancer 
patients can vary among Italian hospitals in terms of 
molecular alterations tested and testing techniques used.
Decreasing the adoption of single-gene testing (SGT) 
techniques in favour of next-generation sequencing 
(NGS) use can lead to cost reduction. Testing a mini-
mum number of patients and molecular alterations might 
be necessary to generate savings.
The number of different molecular alterations to be 
tested is expected to grow in the near future along with 
the potential savings generated by the use of NGS.
1  Introduction and Research Question
Next-generation sequencing (NGS) is a technology that 
allows the simultaneous sequencing of selected regions 
of the genome [targeted sequencing (TS)] up to the whole 
exome [whole exome sequencing (WES)] or whole genome 
[whole genome sequencing (WGS)] [1, 2]. NGS is currently 
used to identify mutations for diagnostic and therapeutic 
purposes in clinical practice (CP) or in the context of specifi-
cally designed clinical trials [3].
Growing interest in NGS has raised the question of its 
value for money (cost-effectiveness) and sustainability 
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(budget impact) compared to the traditional single-gene 
testing (SGT) approach.
In Italy, the SGT-based approach is usually carried out 
in laboratories where the NGS technology is not available, 
and consists of detecting those biomarkers that are drugga-
ble with treatments approved and reimbursed by the Italian 
Drug Agency (AIFA). For example, advanced non-small-cell 
lung cancer (aNSCLC) patients can be treated with specific 
anti-epidermal growth factor receptor (anti-EGFR), anti-
anaplastic lymphoma kinase (anti-ALK), or anti-receptor 
tyrosine kinase (anti-ROS) drugs; these biomarkers can be 
tested with single tests based on real-time polymerase chain 
reaction (RT-PCR), single-gene sequencing, in situ hybridi-
zation techniques, and immunohistochemistry. Alternatively, 
the NGS-based approach aims at simultaneously evaluating 
all the actionable biomarkers regardless of AIFA approval 
and reimbursement.
Three recent papers investigated the challenges posed by 
economic evaluations applied to NGS [4] and systemati-
cally reviewed the most recent evidence on the economic 
impact of the NGS-based versus SGT-based approach [5, 6]. 
For cost estimates, these reviews found huge variations in 
both methods (e.g. gross costing vs bottom-up approach) and 
their findings. Some studies estimated the comprehensive 
diagnostic pathway costs (including patient consultations 
and admissions), while others focused on genetic sequenc-
ing. The reviews raised criticisms not only for the heteroge-
neity of methods used, but also because many cost analyses 
did not present data transparently and did not fully declare 
the cost items included [5], thus limiting data comparability 
and transferability. Review authors advocated for the produc-
tion of guidelines on the costing of diagnostic pathways [6]. 
The main limitations found in the studies included in the 
reviews are that they (1) rarely relied on microcosting, which 
is particularly required for testing in heterogeneous patient 
populations; (2) were mostly retrospective analyses, whose 
completeness depends on data availability; (3) represented a 
broad clinical spectrum of genetic disorders; (4) were often 
carried out on a small sample size; and (5) adopted a sim-
plistic approach, assuming that NGS may substitute all cur-
rent procedures adopted as SGT.
The present study aimed to compare the costs of the 
NGS-based approach with different TS panels to those of 
the SGT-based approach, overcoming most of the limitations 
raised for other studies and adopting a dynamic approach, 
i.e. comparing different testing scenarios, where NGS with 
different TS panels is gradually integrated into the SGT-
based approach. Furthermore, we estimated the threshold, 
in terms of the number of patients, where the NGS-based 
approach becomes less costly than the SGT-based approach.
The analysis has been carried out in Italy, where NGS 
testing is currently not reimbursed at the national level, since 
it is not included in the Italian basket of healthcare goods 
and services centrally defined by the national Ministry of 
Health. However, the regions that are responsible for the 
delivery of healthcare and the relevant budget may provide 
health services beyond this level at their own expenses [7]. 
Since inpatient and outpatient services, including diagnostic 
testing, are paid on a fee-for-episode basis, reimbursement 
of NGS at the regional level would require that the Regional 
Government set the relevant fee. According to a report pub-
lished in 2017, this has happened only in the largest Ital-
ian region (Lombardy) so far (€2072) [8]. The same report 
illustrates the availability of NGS sequencers in four regions, 
accounting for 35% of the Italian population: at least one 
NGS sequencer in 40% of hospitals (our elaboration on [8, 
9]), with an estimate of one sequencer per 2.4 per million 
inhabitants. There is not, to our best knowledge, a nation-
wide analysis of the use of NGS technologies in Italy.
The current analysis focused on non-small-cell lung 
cancer (NSCLC) and unresectable metastatic colon-rectal 
cancer (mCRC). NSCLC is the first and third leading cause 
of tumour-related deaths in Italy for men (26% of deaths) 
and women (11% of deaths), respectively. The diagnosis 
frequently occurs in advanced stages (aNSCLC), where the 
current therapies have limited efficacy, contributing to poor 
outcomes (15.8% 5-year survival rate) [10]. Unresectable 
mCRC is the second most frequent cancer in Italy both in 
terms of incidence and deaths, with a 5-year survival rate 
of 66% (colon cancer) and 62% (rectal cancer) [10]. Both 
diseases can be treated with targeted therapies, but the future 
role played by NGS-based techniques has been differently 
envisaged, with an expected increasing importance for 
NSCLC [11, 12] and higher uncertainty for mCRC.
2  Methods
The comparison between the SGT-based and NGS-based 
approaches in molecular alteration testing focused on 
aNSCLC and mCRC patients (first- and second-line treat-
ments), with 45% of patients treated with second-line ther-
apy for aNSCLC [13] and 49.5% of patients treated with 
second-line therapy for mCRC [14]. The cost analysis was 
conducted considering the hospital perspective.
The molecular alterations considered were as follows:
• aNSCLC: epidermal growth factor receptor (EGFR), 
kirsten rat sarcoma viral oncogene (KRAS), mesenchy-
mal-epithelial transition factor (MET) exon 14 skipping, 
and B-Raf and V-Raf murine sarcoma viral oncogene 
homolog B (BRAF) mutations; anaplastic lymphoma 
kinase (ALK), ROS proto-oncogene 1 receptor tyros-
ine kinase (ROS-1), and rearranged during transfection 
(RET) fusions; mesenchymal-epithelial transition factor 
(MET) amplification; human epidermal growth factor 
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receptor 2 (HER2) status (copy number alteration or 
mutation, protein expression); programmed death-ligand 
1 (PD-L1) status; microsatellite instability (MSI); and 
tumour mutational burden (TMB);
• mCRC : KRAS, neuroblastoma rat sarcoma viral oncogene 
(NRAS), and BRAF mutations; PD-L1 status; O6-meth-
ylguanine DNA methyltransferase (MGMT) promoter 
methylation; MutL homolog 1 (MLH1), MutS homolog 
2 (MSH2), postmeiotic segregation increased 2 (PMS2), 
and MutS homolog 6 (MSH6) protein expression; HER2 
and EGFR status (copy number alteration, protein 
expression); MSI; RET and NTRK1/NTRK2/NTRK3 pan 
neurotrophic tropomyosin receptor kinase (PANTRK) 
fusions; fibroblast growth factor receptor (FGFR2) gene 
status; and TMB.
Three Italian hospitals were selected through convenience 
sampling [15] based on hospital willingness to participate 
and expertise in the diseases considered:
• Scientific Institute for Research, Hospitalisation and 
Health Care (IRCCS) Istituto Nazionale dei Tumori 
(INT) (Milan), which was the pilot centre supporting 
the research protocol design (aNSCLC and mCRC tests 
accounted for 60% of the laboratory activity)
• Teaching Hospital Trust Sant’Andrea (Rome) for 
aNSCLC (whose tests accounted for 75% of the labora-
tory activity)
• IRCCS Istituto Candiolo (Turin) for mCRC (whose tests 
accounted for 10% of the laboratory activity).
Only one hospital was considered for both aNSCLC and 
mCRC; hence, four testing pathways (paths 1, 2, 3, and 4) 
were investigated, two for each target disease (Fig. 1).
The number of aNSCLC patients tested per year were 
364 and 317 for paths 1 and 2, respectively; mCRC patients 
tested per year were 260 and 225 for paths 3 and 4, respec-
tively (2016–2018 average).
Input data were collected through interviews based on a 
semi-structured questionnaire and administered to a CRC/
NSCLC oncologist, pathologist, biologist/molecular biolo-
gist, or laboratory technician. Aggregated data were col-
lected without tracking patient-specific information. The 
pilot hospital (INT) was more intensively involved, with six 
interviews conducted for each path. Information was organ-
ized in a data collection template, validated with follow-
up interviews, and cross-validated with the interviewees 
through a direct check of the template. For the other hospi-
tals, a single interview was conducted with all the involved 
healthcare professionals, and a similar approach to the INT 
review was used. Volume and cost data were collected by 
responders; time spent performing testing was derived from 
a perceptual response based on laboratory staff experience.
For each path, four scenarios were considered:
• Clinical Practice (CP) scenario (i.e. current testing path-
way).
• “Minimum set” scenario, in which molecular tests were 
carried out if strongly recommended by the Italian onco-
logical guidelines [16, 17]. This scenario is usually more 
conservative than the CP scenario.
• “Future CP without TMB” scenario, in which gene test-
ing was expanded to mutations that are expected to be 
routinely included in the future, excluding TMB, i.e. a 
measurement of the mutation load carried by the tumour 
cells that represents a putative predictive biomarker for 
immune therapy [18].
• “Future CP” scenario, in which the CP scenario was 
extended to mutations that are expected to be included 
in future as well as TMB analysis.
The four scenarios were analysed for each of the four 
paths. For the resulting 16 testing cases, two alternative test-
ing approaches were compared:
• SGT-based approach, where molecular alterations were 
tested with single-gene techniques [e.g. fluorescence 
in situ hybridization (FISH), polymerase chain reaction 
(PCR), Sanger sequencing, immunohistochemistry] and 
NGS was used only if standard techniques were unsuit-
able (e.g. for TMB testing).
• NGS-based approach, where molecular alterations were 
tested, as much as possible, through NGS panel testing; 
otherwise, SGT techniques were adopted.
A comparison of the NGS-based and SGT-based 
approaches was conducted as a variation in the transition 
from an SGT-based approach to an NGS-based approach 
(hereafter referred to as ∆SGT→NGS).
The cost items considered were personnel, consumables, 
equipment (purchasing and maintenance), and overheads; 
cost data refer to the year 2018–2019.
For each technique and molecular alteration, the time 
spent by each healthcare professional involved in the testing 
activities was investigated. Given the proportion of fixed and 
variable time defined for each activity, the overall person-
nel time absorbed varied with the average machine satura-
tion (number of samples per run). Saturation depended on 
the volumes of tests performed, maximum number of sam-
ples per run, laboratory opening hours, and required time 
for result delivery (14 calendar days) [19–21]. Considering 
the machine time required to perform the test and person-
nel reporting activities, 8 working days was assumed as the 
deadline to setup the machine and begin the run.
The personnel time absorbed was monetized using the 
hourly gross salary (€61670/year, €61601/year, and €73047/
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year for laboratory technicians, biologists, and pathologists, 
respectively) [22].
Consumables costs were provided for each combina-
tion of techniques and molecular alterations tested. Unit 
costs [including institutional discounts and value-added tax 
(VAT)] were obtained from purchase orders, reflecting the 
actual costs sustained by the hospitals. In particular, NGS 
consumables costs refer to the Ion Torrent™ Ion S5 System, 
provided by one of the involved hospitals and validated by 
the other two.
Equipment purchasing costs were provided by the 
accounting team of one of the involved hospitals. As for 
the consumables, NGS equipment costs refer to the Ion 
Torrent™ Ion S5 System. The other two hospitals did not 
provide their own data, but confirmed that those provided 
could be used as a reference in the analysis. An alternative 
approach was identified in the adoption of publicly available 
tenders for Italian hospitals (years 2017–2018),1 but the data 
were too variable to be considered. Investment deprecia-
tion was set to 5 years [8], while the annual maintenance 
cost was assumed to be 10% [23] of the machine purchasing 
cost. Since aNSCLC/mCRC testing partially accounted for 
the total machine activity, the proportion of time dedicated 
to performing aNSCLC/mCRC tests for each technique 
was applied, and acquisition costs were re-proportionated 
accordingly (Annex Table 1, see the electronic supplemen-
tary material). We assigned to each scenario only those 
equipment and maintenance costs that refer to the specific 
techniques used.
The hospitals involved did not provide the overhead costs, 
and even if they had been provided, the different allocation 
approaches in use (e.g. level of data aggregation, cost items 
included, allocation drivers) would have made it difficult 
to obtain a sound comparison of the specific amount allo-
cated to each technique. Furthermore, there is no reference 
in the Italian literature that can provide guidelines on over-
heads allocation in our specific case. Therefore, we decided 
to adopt the approach used by Schwarze et al., where total 
costs were increased by an additional 20% to account for 
overheads [24].
For each path, an evaluation with varying volumes of 
tested patients was performed to identify the minimum 
number of patients beyond which the NGS-based approach 
became less costly (break-even analysis).
Single-way deterministic sensitivity analysis (DSA) was 
performed for the CP scenario to identify the key model 
drivers. Each parameter was varied by ± 20%. Savings gen-
erated by NGS adoption increased in more advanced sce-
narios, thus the choice of performing the analysis in the CP 
scenario can be considered a conservative approach.
Fig. 1  Research design. Two 
testing pathways for each of the 
diseases considered (paths 1 and 
2 for aNSCLC and paths 3 and 
4 for mCRC) were investi-
gated in three Italian hospitals. 
Four scenarios (“minimum 
set”, “clinical practice” (CP), 
“future CP no TMB”, and 
“future CP”) were defined 
for each testing pathway, and 
cost analyses were conducted 
comparing the SGT-based and 
NGS-based approaches for 
each of the 16 testing cases 
identified. aNSCLC advanced 
non-small-cell lung cancer, 
CP clinical practice, mCRC 
metastatic colon-rectal cancer, 
NGS next-generation sequenc-
ing, SGT single-gene testing, 
TMB tumour mutational burden, 
vs versus 
1 Supplementary material on request.
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3  Results
The results section reports (1) an overview of the input 
data (further information is reported in the annex, see the 
electronic supplementary material), (2) the mean cost per 
patient, (3) the personnel time and cost absorbed for test-
ing activities, (4) the capacity increase, (5) the break-even 
analysis, and (6) the sensitivity analysis.
The results are based on the ∆SGT→NGS comparison, and 
a discussion is presented in the sections below. A complete 
illustration of the results achieved for each testing case is 
provided in Table 1.
3.1  Input Data
The analysis considered the following for each path:
• Molecular alterations tested and testing frequency upon 
the first and second treatment lines in each scenario 
(Annex Table 2, see the electronic supplementary mate-
rial)
• Testing techniques for each molecular alteration, includ-
ing NGS (Annex Table 3, see the electronic supplemen-
tary material)
• Validation and retesting frequency for each molecular 
alteration in case of failure or an inconclusive result and 
the type of technique adopted (Annex Table 4, see the 
electronic supplementary material)
• Time required to perform testing and reporting activities 
for each healthcare professional involved (Annex Table 5, 
see the electronic supplementary material)
• Equipment costs including purchase, depreciation and 
maintenance costs (Annex Table 1, see the electronic 
supplementary material)
• Consumables costs for each technique and molecular 
alteration tested (Annex Table 6, see the electronic sup-
plementary material)
• Overhead costs calculated as percentage (20%) of the 
resulting total cost.
Participating hospitals differed in terms of molecular 
alterations currently tested, expected evolution of the testing 
approach, and techniques adopted. These differences led to a 
different average number of tests per patient (Table 2), rang-
ing from one (path 4), meaning that all the alterations are 
tested with the NGS panel test, to nine (path 3) for the NGS-
based technique, and from 1.3 (path 4) to 12.5 (path 3) for 
the SGT-based technique. Moving from the “minimum set” 
to the “future CP” scenario, the number of tests per patient 
increased, although to a lesser extent, using the NGS-based 
approach, which allows simultaneous testing. The remark-
able difference between path 3 and path 4 in terms of average 
number of tests per patient is mainly due to the considerably 
wider set of molecular alterations tested in path 3 compared 
to path 4 (Table 2).
3.2  Mean Cost Per Patient
The mean cost per patient, including personnel, consuma-
bles, equipment, and overhead costs, is reported in Fig. 2.
The ∆SGT→NGS savings per patient increased in scenarios 
with a larger set of molecular alterations tested. Savings in 
the “minimum set” and “future CP” scenarios ranged from 
€288 to €879, from −€25 (the only case of a cost increment) 
to €522, from €63 to €633, and from €30 to €1249 for paths 
1, 2, 3, and 4, respectively.
The NGS-based approach reduced personnel costs in 
all testing cases. The consumables ∆SGT→NGS costs were 
reduced in all of the testing cases except for path 2 in the 
“minimum set” and CP scenarios. In path 2, less expensive 
SGT techniques were preferred to more expensive techniques 
adopted by other hospitals, making the ∆SGT→NGS savings 
more difficult to achieve. Consumables were the most rel-
evant cost item, and the savings achieved compensated for 
the potential increase in equipment costs. Equipment costs 
increased from the “minimum set” scenario to the “future 
CP” scenario since more molecular alterations need to be 
tested and more testing techniques need to be used. Over-
head costs are proportional to the total cost of personnel, 
consumables, and equipment. The NGS capacity to test mul-
tiple molecular alterations caused the NGS-based approach 
to be less costly than the SGT-based approach in scenarios 
with more comprehensive testing, generating equipment cost 
savings in half of the testing cases considered.
The overall cost comparison is discussed in the following 
sections and is summarized in Table 1.
3.3  Personnel Time
∆SGT→NGS personnel time savings increased progressively in 
scenarios based on more comprehensive testing.
The ∆SGT→NGS overall personnel time savings were 628 h, 
271 h, 103 h, and 333 h for paths 1, 2, 3, and 4, respectively, 
in the “minimum set” scenario and 1369 h, 691 h, 470 h, 
and 919 h, respectively, in the “future CP” scenario (Fig. 3).
The overall time savings for each path are reported in 
Fig. 3. Personnel cost savings, as reported in Table 1, were 
proportional to time savings, ranging from €3618 (path 3, 
“minimum set”) to €48,216 (path 1, “future CP”).
Personnel time saved was converted into the number of 
additional patients who could be potentially tested by the 
hospital (Table 3) using an NGS-based approach, providing 
an estimation of the capacity increase. This indicator was 
calculated by dividing the overall personnel time savings 
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Table 2  Average number of tests per patient. Each path differs in terms of molecular alterations tested and testing frequency in the respective 
scenarios and in terms of testing techniques used, thus, resulting in a specific number of tests per patient
aNSCLC advanced non-small-cell lung cancer, CP clinical practice, mCRC metastatic colon-rectal cancer, NGS next-generation sequencing, 
SGT single-gene testing, TMB tumour mutational burden, ∆SGT→NGS variation in the transition from an SGT-based approach to an NGS-based 
approach
Path 1: aNSCLC Path 2: aNSCLC
Minimum set CP Future CP no 
TMB
Future CP Minimum set CP Future CP no 
TMB
Future CP
SGT-based 5.2 6.7 7.2 8.2 4.6 5.2 5.6 6.7
NGS-based 2.1 2.1 2.1 2.1 2.1 2.6 2.6 2.6
∆SGT→NGS 3.1 4.6 5.1 6.1 2.5 2.6 3.0 4.1
Path 3: mCRC Path 4: mCRC 
Minimum set CP Future CP no 
TMB
Future CP Minimum set CP Future CP no 
TMB
Future CP
SGT-based 7.1 11.6 11.5 12.5 1.3 2.6 2.5 3.5
NGS-based 5.1 8.4 9.0 9.0 1.0 1.0 1.0 1.0
∆SGT→NGS 2.0 3.2 2.5 3.5 0.3 1.6 1.5 2.5
Fig. 2  Mean cost per patient. The mean cost per patient comparing 
the SGT-based and NGS-based approaches is shown for each testing 
case considering personnel, consumables, equipment (purchasing and 
maintenance), and overhead costs to perform all the required tests. 
aNSCLC advanced non-small-cell lung cancer, CP clinical practice, 
mCRC metastatic colon-rectal cancer, NGS next-generation sequenc-
ing, SGT single-gene testing, TMB tumour mutational burden
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by the average personnel time spent performing all the tests 
required for a patient in the NGS-based approach.
Additional testable patients generated by the NGS-based 
approach ranged from 506, 142, 36, and 206 for paths 1, 2, 
3, and 4, respectively, in the “minimum set” scenario, and 
a maximum of 923, 294, 56, and 397, in the “future CP” 
scenario.
3.4  Break‑Even Analysis
The break-even volume represents the number of tested 
patients where the SGT-based cost per patient equals the 
NGS-based cost; above this threshold, an NGS-based 
approach generates savings.
Break-even charts for path 3 are presented in Fig. 4, while 
Table 4 illustrates the volumes and break-even thresholds for 
all paths. The larger the number of tested molecular altera-
tions, the more the testing process can benefit from the NGS 
capacity to test a wider range of molecular alterations in a 
single run; the SGT-based approach would need to involve 
different techniques, hence requiring a higher number of 
tests. Table 4 shows that, moving from the “minimum set” 
to the “future CP” scenario, the patient break-even volume 
(if applicable) decreases and the NGS savings are easier to 
achieve. 
3.5  Deterministic Sensitivity Analysis
Deterministic sensitivity analyses were performed for each 
path in the CP scenario, where all key parameters were var-
ied by ± 20%. In all the paths, consumables costs (used for 
the Sanger technique in paths 1 and 3 and for NGS or mass 
spectrometry for paths 2 and 4) were the most impactful 
variable, as shown in Fig. 5. The variation within the deter-
mined range of the most impactful parameter (impact on 
∆SGT→NGS savings is ±€39,183, ±€17,667, ±€26,760, and 
±€16,200 for paths 1, 2, 3, and 4, respectively) caused the 
SGT-based approach to be slightly less expensive (€8215) 
than the NGS-based approach in path 2 only.
4  Discussion
The introduction of NGS has enhanced the potential detec-
tion of mutations, with an important impact on the diagnosis 
and treatment of many diseases. Although diagnostic pro-
cedures represent a small proportion of total pathway costs, 
growing attention has been paid to the impact of NGS on the 
budget and its cost-effectiveness compared to the standard 
single-testing approach. Three recent papers on economic 
studies on NGS have raised concerns on the way cost analy-
ses have been carried out [4–6]. Furthermore, they revealed 
that the evidence on NGS costs is quite poor for Europe, and 
no data exist for Italy.
Fig. 3  ∆SGT→NGS overall 
personnel time savings. The 
overall personnel time savings 
generated by the NGS-based 
approach are shown for each 
testing case. aNSCLC advanced 
non-small-cell lung cancer, CP 
clinical practice, mCRC meta-
static colon-rectal cancer, NGS 
next-generation sequencing, 
SGT single-gene testing, TMB 
tumour mutational burden
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The present study aimed to cover the information gap 
for Italy, investigating the costs of different diagnostic 
approaches (NGS-based vs SGT-based) in three Italian 
hospitals according to different scenarios characterized by 
an increasing number of mutations analysed. The current 
study was planned before the two systematic reviews were 
published. Notwithstanding, it was designed to address most 
of the limitations of previous studies that the two reviews 
highlighted. Our analysis compared different scenarios 
(dynamic approach) where NGS was gradually implemented 
and was not a virtual comparison between a full adoption 
of NGS and single testing. A microcosting approach was 
adopted because this approach is suggested if cost analyses 
are carried out in heterogeneous patients. We also detailed 
the cost items and methods used for estimation. Another 
advantage of the current study is that the mean cost per 
patient was estimated instead of the mean cost per test, to 
take into account possible double testing.
According to our estimates, the diagnostic mean cost 
per patient ranges from €501 to €3150 for the NGS-based 
approach and from €476 to €3783 for the SGT-based 
approach. Our results are comparable to those from most 
other studies relying on microcosting analyses and applied 
to cancer care. Two studies were conducted in the USA 
[25] and the Netherlands [26]. The relevant estimates 
included pre-analytics and analytics labour, equipment 
and consumables, bioinformatic data analysis, reporting, 
and overhead costs. Depending on the procedure used, the 
full assay cost per sample ranged between US$699 (€655 
[27]) and US$2428 (€2275 [27]) in the USA and between 
Table 3  Overall additional patients due to ∆SGT→NGS time savings
Additional patients who could be potentially tested in each testing 
case if ∆SGT→NGS personnel time savings were used to increase the 
testing activity and if the NGS-based approach was adopted
aNSCLC advanced non-small-cell lung cancer, CP clinical practice, 
mCRC metastatic colon-rectal cancer, NGS next-generation sequenc-
ing, SGT single-gene testing, TMB tumour mutational burden, 
∆SGT→NGS variation in the transition from an SGT-based approach to 
an NGS-based approach
Capacity increase (patients)
Minimum set CP Future CP 
no TMB
Future CP
Path 1—aNSCLC 506 786 852 923
Path 2—aNSCLC 142 119 164 294
Path 3—mCRC 36 43 27 56
Path 4—mCRC 206 321 294 397
Fig. 4  Break-even analysis (path 3). The mean cost per patient for the 
SGT-based and NGS-based approaches in path 3 is displayed for each 
scenario and reported as a function of patient volume. The number 
of patients tested by the hospital (“volume path 3”) and the threshold 
necessary for the NGS-based approach to generate savings (“break-
even”) are shown. CP clinical practice, NGS next-generation sequenc-
ing, SGT single-gene testing, TMB tumour mutational burden
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€606 and €2668 in the Netherlands. The Dutch study also 
assumed high productivity rates: 24 samples per test, one 
test per week, and 85% conclusive results (no additional tests 
required). Another recent study carried out in a single centre 
in the UK estimated the cost of genome sequencing for a 
cancer case equal to £6841 (€7754 [28]), £3420 (€3876 [28]) 
per genome. In all studies, consumables represent the most 
important cost item [24].
Our analysis reveals that by moving from the SGT-based 
to the NGS-based approach, hospitals can reduce sequencing 
Table 4  Break-even analysis 
volumes
The table illustrates, for each testing case, the break-even volume; “>  0” represents the NGS-based 
approach being less expensive for any number of patients tested
aNSCLC advanced non-small-cell lung cancer, CP clinical practice, mCRC metastatic colon-rectal cancer, 
NGS next-generation sequencing, TMB tumour mutational burden
Disease Path Hospital volume 
(patients/year)
Break-even volume (patients)
Minimum set CP Future CP no 
TMB
Future CP
aNSCLC 1 364 60 > 0 > 0 > 0
2 317 – 70 > 0 > 0
mCRC 3 260 220 160 180 > 0
4 225 180 > 0 > 0 > 0
Fig. 5  Deterministic sensitivity analysis (CP scenario). The results 
of the DSA are shown in the CP scenario and are displayed in a tor-
nado diagram (the 15 most impactful variables are included). Input 
data were varied (± 20%), and impacts on the ∆SGT→NGS savings were 
observed. CP clinical practice, DSA deterministic sensitivity analysis, 
FISH fluorescence in situ hybridization, IHC immunohistochemistry, 
ISH in situ hybridization, mCRC metastatic colon-rectal cancer, NGS 
next-generation sequencing, RT-PCR real-time polymerase chain 
reaction, SGT single-gene testing, TMB tumour mutational burden, 
∆SGT→NGS variation in the transition from an SGT-based approach to 
an NGS-based approach
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costs by €30–€1249 per patient depending on the scenario, 
and only in one testing case is the SGT-based approach less 
costly. The savings per patient tested are higher in scenarios 
with a more comprehensive set of molecular alterations 
tested. Hence, the higher the number of mutations screened, 
the more the NGS-based approach is less costly than the 
SGT-based one. This result was not surprising, since the 
SGT-based approach is less suitable when different altera-
tions should be found. Another important result is that in all 
testing cases, the personnel time dedicated to sequencing is 
reduced, thus providing the opportunity to reallocate this 
saved time in other more labour-intensive activities.
Our research provides another interesting finding, i.e. the 
minimum number of patients needed to make the NGS-based 
approach less costly than the SGT-based one. The break-
even point ranged from 0 to 220 depending on the complex-
ity of the analysis, the hospital, and the disease (aNSCLC 
and mCRC). Other studies have shown only that the mean 
assay cost significantly decreased with higher volumes [26].
These findings have important implications for hospitals 
and regulators. There is clear evidence that using the NGS-
based versus SGT-based approach is advantageous from an 
economic perspective, provided that a minimum number 
of patients are screened. This evidence should address the 
selection of centres accredited for providing NGS-based 
diagnostic procedures for the whole population.
Most of the other studies have estimated the cost per sam-
ple, which is useful for other purposes, i.e. comparing the 
economic efficiency of different laboratories or determining 
the fee for service payers should pay laboratories. Having 
estimated in our study the cost per patient may also help 
convert a fee-for-service-based funding system into a fee-
for-episode-based funding system. A fee-for-episode-based 
funding system may push healthcare providers to better man-
age the whole sequencing/diagnostic process.
We are aware that the current study has some limitations. 
The microcosting analysis was applied to a small sample 
of research-oriented and teaching hospitals, which were 
selected on the grounds of their willingness to participate 
in the survey (sample of convenience). Although these hos-
pitals cannot therefore be considered prototypical of Italian 
hospitals, these centres are likely to represent, in the future, 
accredited reference laboratories for NGS-based techniques. 
It should also be noted that two of the three studies relying 
on the microcosting approach mentioned before were car-
ried out in one single centre [24, 26]. Another limitation 
of our study is that most of the input data were retrieved 
from interviews with healthcare professionals due to limited 
accessibility to other analyses (e.g. time and motion analy-
sis for the time dedicated by each healthcare professional). 
However, confirmatory, repeated interviews were carried out 
to cross-check the robustness of the answers. Furthermore, 
we had to rely on benchmark data for those centres who 
did not provide all the required information (e.g. equipment 
purchasing costs and NGS consumables costs for path 2 and 
path 4) and on international published data for overhead 
costs, since data for the three centres were not available and 
there is no available evidence for Italy. Another limitation 
is the retrospective nature of the study; the most recent sys-
tematic review on health economics studies applied to NGS 
has recommended a prospective analysis [5]. Finally, this is a 
partial analysis comparing two alternative approaches (NGS-
based vs SGT-based) in different scenarios from a cost per-
spective. This result should be integrated with process (e.g., 
diagnostic yield) and health (e.g., quality-adjusted life years) 
outcomes to have a complete set of information for decision-
makers. A cost-effectiveness analysis was beyond our scope 
and would have required reliable data on the two sequencing 
strategies in all scenarios considered.
Despite these limitations, our study provides insights into 
the cost of NGS in Italian laboratories comprehensively test-
ing mutations in aNSCLC and mCRC.
5  Conclusion
Although diagnostic procedures do not represent the most 
relevant cost of cancer patient treatment, they will increas-
ingly play a central role in clinical decision-making. The 
optimization of diagnostic procedures is important for at 
least two reasons: (1) mutation-driven treatments have 
steadily increased in recent years, and (2) tumour-agnostic 
treatments based on molecular alterations occurring across 
a variety of different tumour types have been recently 
approved by the Food and Drug Administration (FDA) [29].
Along this line, our study showed that the NGS-based 
approach is less costly than the SGT-based approach, pro-
vided that a minimum number of patients are tested. This 
result can be considered for regulatory purposes, including 
the rules to accredit hospitals for NGS analysis, as well as 
for access issues (e.g., whether NGS can be covered by third-
party payers), and finally for economic analysis, since NGS 
testing may accelerate the use of medicines and investment 
decisions.
We are perfectly aware that the decision to adopt an 
NGS approach should consider not only costs but also the 
effectiveness, organizational impact, availability of suitable 
treatments, its use in CP or in clinical trials, and data con-
fidentiality issues, among other factors. Nevertheless, the 
present analysis aimed to generate evidence on one of the 
key drivers of decision-making in healthcare.
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